Power Struggle at NIH: Political Appointees Shift Leadership Landscape

A significant shift in leadership dynamics is occurring at the National Institutes of Health (NIH) as the Trump administration increases its political influence over the agency. Historically, NIH, the United States’ premier biomedical research institution, has operated with minimal political interference. However, recent appointments and changes to hiring practices signal a new era of potential politicization, raising concerns among current and former officials.

When a new presidential administration takes office, it is responsible for filling approximately 4,000 positions across the federal landscape. While well-known roles like the secretary of state receive ample attention, many obscure positions often go unnoticed. In the case of scientific agencies such as NIH, there has traditionally been a reluctance to fill senior roles with political appointees. This has allowed scientists to oversee research funding and operations with minimal interference from political leaders.

As of November 2025, NIH had a workforce of around 17,500 employees. Among these, only a few were political appointees, leaving much of the leadership selection process in the hands of staff scientists and external experts. This long-standing practice ensured that decisions regarding the leadership of the agency’s 27 institutes and centers remained largely independent of direct White House oversight.

However, the arrival of the Trump administration has prompted questions about the future of this status quo. Observers note that the administration’s increased political appointments in key NIH roles, along with changes to the traditional hiring process, indicate a shift towards greater political oversight. The perception of NIH as a progressive institution has drawn scrutiny from conservative lawmakers, particularly in light of criticisms surrounding the agency’s funding decisions during the COVID-19 pandemic.

One of the most recognizable figures in this context is Anthony Fauci, who led the National Institute of Allergy and Infectious Diseases until his retirement in 2022. Fauci’s prominence during the pandemic made him a polarizing figure, especially among conservatives who viewed him as an unelected official wielding significant power. This polarization has contributed to the ongoing debate about the agency’s direction and leadership.

In light of these dynamics, there have been calls for reforms in NIH’s leadership structure. In 2019, the agency announced plans to implement term limits for midlevel roles to diversify management. Recently, Joseph Marine, a physician and researcher at Johns Hopkins University, advocated for five to ten-year term limits for institute directors, emphasizing that “regular turnover of leadership brings fresh ideas and a healthy reassessment of priorities.”

Following his election victory, Donald Trump appointed Jay Bhattacharya—a vocal critic of NIH—as the agency’s head. This decision aligns with the administration’s push for reforms and greater political control over NIH. Former official Mike Lauer, who previously oversaw NIH’s external grants program, noted signs of increased political scrutiny on institute directors prior to Trump’s second inauguration.

Lauer highlighted a specific recommendation from Project 2025, a roadmap produced by the Heritage Foundation, which advocates for more political oversight in scientific funding. The report argued that funding for scientific research should not be controlled by “a small group of highly paid and unaccountable insiders.”

Following Trump’s inauguration, several senior NIH officials, including Lawrence Tabak, were placed on administrative leave or left the agency altogether. The number of political appointees at NIH has increased, with nine individuals appointed by late June 2025, up from four the previous year. Notably, among these appointees is Seana Cranston, a former Republican Congressional staffer, now serving as chief of staff to the NIH Director.

Despite these changes, NIH still has fewer political appointees compared to other federal agencies, such as NASA. However, the administration’s departure from traditional hiring practices for NIH’s institute and center directors has raised alarms. In the spring of 2025, five directors, including the head of the National Institute of Allergy and Infectious Diseases, were removed from their positions without clear justification.

As vacancies continue to grow, there are concerns regarding the hiring process for these critical roles. NIH insiders have noted that the agency has not formed the typical search committees, which traditionally include both NIH career scientists and external experts. Instead, the Department of Health and Human Services stated that an NIH leadership team with experience in scientific management would evaluate applicants and make recommendations. However, details regarding the composition of this team remain vague.

Critics within the agency express apprehension about the implications of this shift. Mark Histed, an NIH scientist, emphasized the importance of external members on search committees to prevent politicization. He noted that a diverse committee makes it more challenging for political agendas to dominate the hiring process. Such practices have historically contributed to NIH’s status as a leading scientific institution, fostering an environment conducive to groundbreaking research.

Members of Congress have taken notice of these changes. In the current appropriations bill, lawmakers have urged NIH to uphold its longstanding practice of involving external scientists in the search process for leadership roles. Additionally, Diana DeGette, a Democratic representative from Colorado, has introduced a bill aimed at protecting NIH from political interference, proposing to limit the number of political appointees within the agency.

The tug-of-war between political control and bureaucratic independence is not new. Lauer pointed out that the balance between these forces often influences how agencies operate. Politicians argue that increased control can enhance accountability and responsiveness to the electorate. However, the potential downsides include short-term thinking, unstable budgets, and a loss of expertise.

Political scientist Mark Richardson noted a correlation between political disagreements and the degree of control exerted by administrations over specific agencies. NIH, historically aligned with bipartisan support, is experiencing a shift as political conflict expands to include scientific institutions.

The ongoing developments at NIH reflect broader tensions between scientific integrity and political influence. As the agency navigates this evolving landscape, the implications for biomedical research and public health remain to be seen.